
EquitySector - HealthcareVery High Risk
Direct
NAV (22-Jan-26)
Returns (Since Inception)
Fund Size
₹2,771 Cr
Expense Ratio
0.48%
ISIN
INF769K01ED6
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
02 Jun 2018
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+0.43%
— (Cat Avg.)
3 Years
+22.10%
+20.98% (Cat Avg.)
5 Years
+16.43%
+14.33% (Cat Avg.)
Since Inception
+20.40%
— (Cat Avg.)
| Equity | ₹2,755.76 Cr | 99.46% |
| Others | ₹15.07 Cr | 0.54% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹344.7 Cr | 12.44% |
| Divi's Laboratories Ltd | Equity | ₹237.6 Cr | 8.57% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹191.52 Cr | 6.91% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹160.6 Cr | 5.80% |
| Cipla Ltd | Equity | ₹153.86 Cr | 5.55% |
| Lupin Ltd | Equity | ₹144.85 Cr | 5.23% |
| Dr Reddy's Laboratories Ltd | Equity | ₹120.34 Cr | 4.34% |
| Aurobindo Pharma Ltd | Equity | ₹117.41 Cr | 4.24% |
| Fortis Healthcare Ltd | Equity | ₹116.96 Cr | 4.22% |
| Ipca Laboratories Ltd | Equity | ₹95.85 Cr | 3.46% |
| Laurus Labs Ltd | Equity | ₹92.05 Cr | 3.32% |
| Alkem Laboratories Ltd | Equity | ₹89.97 Cr | 3.25% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹89.36 Cr | 3.22% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹87.95 Cr | 3.17% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹85.86 Cr | 3.10% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹85.37 Cr | 3.08% |
| Torrent Pharmaceuticals Ltd | Equity | ₹83.05 Cr | 3.00% |
| OneSource Specialty Pharma Ltd | Equity | ₹81.26 Cr | 2.93% |
| Sai Life Sciences Ltd | Equity | ₹74.61 Cr | 2.69% |
| Mankind Pharma Ltd | Equity | ₹52.92 Cr | 1.91% |
| Gland Pharma Ltd | Equity | ₹50.21 Cr | 1.81% |
| Anthem Biosciences Ltd | Equity | ₹34.29 Cr | 1.24% |
| Cohance Lifesciences Ltd | Equity | ₹27.38 Cr | 0.99% |
| Rubicon Research Ltd | Equity | ₹25.38 Cr | 0.92% |
| Deepak Nitrite Ltd | Equity | ₹21.5 Cr | 0.78% |
| Treps | Cash - Repurchase Agreement | ₹18.87 Cr | 0.68% |
| Dr. Lal PathLabs Ltd | Equity | ₹17.23 Cr | 0.62% |
| Sagility Ltd | Equity | ₹16.44 Cr | 0.59% |
| Corona Remedies Ltd | Equity | ₹16.2 Cr | 0.58% |
| Syngene International Ltd | Equity | ₹14.79 Cr | 0.53% |
| Sudeep Pharma Ltd | Equity | ₹12.35 Cr | 0.45% |
| Neogen Chemicals Ltd | Equity | ₹12.19 Cr | 0.44% |
| Net Receivables / (Payables) | Cash | ₹-4.03 Cr | 0.15% |
| Wockhardt Ltd | Equity | ₹1.51 Cr | 0.05% |
| Mirae Asset Liquid Dir Gr | Mutual Fund - Open End | ₹0.23 Cr | 0.01% |
| Biocon Ltd | Equity | ₹0.2 Cr | 0.01% |
Large Cap Stocks
39.70%
Mid Cap Stocks
33.78%
Small Cap Stocks
25.97%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹2,722.07 Cr | 98.24% |
| Basic Materials | ₹33.7 Cr | 1.22% |
Standard Deviation
This fund
16.19%
Cat. avg.
15.84%
Lower the better
Sharpe Ratio
This fund
0.99
Cat. avg.
0.98
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.79
Higher the better

Since July 2018
ISIN INF769K01ED6 | Expense Ratio 0.48% | Exit Load 1.00% | Fund Size ₹2,771 Cr | Age 7 years 7 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹2,36,631 Cr
Address
Unit No. 606, 6th Floor, Mumbai, 400 098
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments